Assessment of Circulating Biomarkers in Relation to Various Stages of Diabetic Retinopathy in Type 2 Diabetic Patients-A Cross Sectional Study

Author(s): Nalini Mathala*, Annapurna Akula, Sharat Hegde, Raghava Bitra, Virender Sachedev

Journal Name: Current Diabetes Reviews

Volume 16 , Issue 4 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Aim: The aim of this study is to examine the relationship between inflammatory markers, and diabetic retinopathy in type II diabetic patients.

Methods: The study was a cross-sectional study included 150 type 2 diabetic patients who were divided into 3 groups. 50 in each group are divided as Diabetic patients without retinopathy (DM, n=50), nonproliferative diabetic retinopathy patients (NPDR, n=50), proliferative diabetic retinopathy patients (PDR, n=50). All the patients were subjected to complete clinical examination and laboratory investigations, such as fasting and postprandial blood glucose, serum creatinine, lipid profile tests, glycosylated haemoglobin (HbA1c), fasting insulin, serum inflammatory markers (TNF-alpha, C-reactive protein) and serum VEGF.

Results: The study revealed from the multivariate analysis that age, duration and WHR (waist-hip ratio) are potent risk factors responsible for the risk of Diabetic retinopathy. Similarly, serum creatinine, CRP, TNF- alpha and VEGF are significantly higher in diabetic patients with retinopathy compared to diabetic patients without retinopathy.

Conclusion: The study concluded that inflammation was associated with severe diabetic retinopathy in patients with well-controlled diabetes. A possible relationship was provided between the risk factors and biomarkers which are responsible for Diabetic retinopathy. Hence, modifying the risk factors risk and development of severe diabetic retinopathy can be reduced.

Keywords: Type 2 diabetes, inflammation, VEGF, TNF- alpha, diabetic, cross-sectional study.

[1]
Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 2016; 39(Suppl. 2): S244-52.
[http://dx.doi.org/10.2337/dcS15-3015] [PMID: 27440839]
[2]
Roy MS, Janal MN, Crosby J, Donnelly R. Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes. Invest Ophthalmol Vis Sci 2013; 54(8): 5471-80.
[http://dx.doi.org/10.1167/iovs.13-12212] [PMID: 23847308]
[3]
Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol 2012; 19(1): 52-9.
[http://dx.doi.org/10.4103/0974-9233.92116] [PMID: 22346115]
[4]
Meleth AD, Agrón E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46(11): 4295-301.
[http://dx.doi.org/10.1167/iovs.04-1057] [PMID: 16249511]
[5]
Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006; 20(12): 1366-9.
[http://dx.doi.org/10.1038/sj.eye.6702138] [PMID: 16284605]
[6]
Gadkari SS, Maskati QB, Nayak BK. Prevalence of diabetic retinopathy in India: The All India Ophthalmological Society Diabetic Retinopathy Eye Screening Study 2014. Indian J Ophthalmol 2016; 64(1): 38-44.
[http://dx.doi.org/10.4103/0301-4738.178144] [PMID: 26953022]
[7]
Razia A Ahmed SN. Khalil, Mohammad A.A.Al-Qahtani, Diabetic retinopathy and associated risk factors in diabetes type 2 patients in Abha, Saudi Arabiaǁ J Family Community Med 2016; 18-24.
[http://dx.doi.org/10.4103/2230-8229.172225]
[8]
Lima VC, Cavalieri GC, Lima MC, Nazario NO, Lima GC. Risk factors for diabetic retinopathy: a case-control study. Int J Ophthalmol 2017; 17: 1615-9.
[http://dx.doi.org/10.1186/s40942-016-0047-6] [PMID: 27847639]
[9]
Senthilvel S, Sureshbabu J. Study on risk factors associated with diabetic retinopathy among the patients with type 2 diabetes mellitus in South India. Int J Ophthalmol 2017. Vol. 17.
[10]
Mahdy W. Nada1, Doaa Attia Abdel-Moety. Evaluation of serum and aqueous humor vascular endothelial growth factor in neovascular glaucoma. Open J Ophthalmol 2017; 7: 79-87.
[http://dx.doi.org/10.4236/ojoph.2017.72012]
[11]
Simó-Servat O, Simó R, Hernández C. Circulating biomarkers of diabetic retinopathy: an overview based on physiopathology. J Diabetes Res 2016; 20165263798
[http://dx.doi.org/10.1155/2016/5263798] [PMID: 27376090]
[12]
Peng D, Wang J, Zhang R, et al. C-reactive protein genetic variant is associated with diabetic retinopathy in Chinese patients with type 2 diabetes. BMC Endocr Disord 2015; 15: 8.
[http://dx.doi.org/10.1186/s12902-015-0006-5] [PMID: 25887518]
[13]
Rajab HA, Baker NL, Hunt KJ, et al. The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. J Diabetes Complications 2015; 29(1): 108-14.
[http://dx.doi.org/10.1016/j.jdiacomp.2014.08.004] [PMID: 25441222]
[14]
Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem 2016; 117(11): 2443-53.
[http://dx.doi.org/10.1002/jcb.25575] [PMID: 27128219]
[15]
Zhang Z-H, Chen Q-Z, Jiang F, et al. Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy. Mol Med Rep 2017; 15(2): 573-80.
[http://dx.doi.org/10.3892/mmr.2016.6048] [PMID: 28000874]
[16]
Wu H, Hwang D-K, Song X, Tao Y. Association between aqueous cytokines and diabetic retinopathy stage. J Ophthalmol 2017; 20179402198
[http://dx.doi.org/10.1155/2017/9402198] [PMID: 28680705]
[17]
Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci 2018; 19(4): 942.
[http://dx.doi.org/10.3390/ijms19040942] [PMID: 29565290]
[18]
Pusparajah P, Lee L-H, Abdul Kadir K. Molecular markers of Diabetic retinopathy: Potential screening tool of the future. Front Physiol 2016; 7: 200.
[http://dx.doi.org/10.3389/fphys.2016.00200] [PMID: 27313539]
[19]
Paine SK, Mondal LK, Borah PK, Bhattacharya CK, Mahanta J. Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy. Mol Vis 2017; 23: 356-63.
[PMID: 28680264]
[20]
Yu CG, Yuan SS, Yang LY, et al. Angiopoietin-like 3 Is a potential biomarker for retinopathy in type 2 diabetic patients. Am J Ophthalmol 2018; 191: 34-41.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 4
Year: 2020
Published on: 28 April, 2020
Page: [402 - 409]
Pages: 8
DOI: 10.2174/1573399815666190823155534
Price: $65

Article Metrics

PDF: 17
HTML: 2